ID   SUM159R
AC   CVCL_C9AN
SY   SUM-159PT(R)
DR   BioGRID_ORCS_Cell_line; 1396
DR   Wikidata; Q123033572
RX   PubMed=26735014;
RX   PubMed=32416067;
CC   Group: Triple negative breast cancer (TNBC) cell line.
CC   Selected for resistance to: ChEBI; CHEBI:137113; JQ1.
CC   Sequence variation: Mutation; HGNC; 5173; HRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000012612; Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Leu (c.3140A>T); ClinVar=VCV000013653; Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Val157_Arg158insLeu (c.472_473ins3); Zygosity=Unspecified (from parent cell line).
CC   Omics: CRISPR phenotypic screen.
CC   Derived from site: In situ; Breast; UBERON=UBERON_0000310.
DI   NCIt; C5161; Breast pleomorphic carcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_5423 ! SUM159PT
SX   Female
AG   71Y
CA   Cancer cell line
DT   Created: 05-10-23; Last updated: 30-01-24; Version: 2
//
RX   PubMed=26735014; DOI=10.1038/nature16508;
RA   Shu S.-K., Lin C.Y., He H.-S.H., Witwicki R.M., Tabassum D.P.,
RA   Roberts J.M., Janiszewska M., Huh S.J., Liang Y., Ryan J., Doherty E.,
RA   Mohammed H., Guo H., Stover D.G., Ekram M.B., Brown J., D'Santos C.,
RA   Krop I.E., Dillon D., McKeown M.R., Ott C., Qi J., Ni M., Rao P.K.,
RA   Duarte M., Wu S.-Y., Chiang C.-M., Anders L., Young R.A., Winer E.,
RA   Letai A.G., Barry W.T., Carroll J.S., Long H., Brown M.A., Liu X.-L.S.,
RA   Meyer C.A., Bradner J.E., Polyak K.;
RT   "Response and resistance to BET bromodomain inhibitors in
RT   triple-negative breast cancer.";
RL   Nature 529:413-417(2016).
//
RX   PubMed=32416067; DOI=10.1016/j.molcel.2020.04.027;
RA   Shu S.-K., Wu H.-J., Ge J.Y., Zeid R., Harris I.S., Jovanovic B.,
RA   Murphy K., Wang B.-B., Qiu X.-T., Endress J.E., Reyes J., Lim K.,
RA   Font-Tello A., Syamala S., Xiao T.-F., Reddy Chilamakuri C.S.,
RA   Papachristou E.K., D'Santos C., Anand J., Hinohara K., Li W.,
RA   McDonald T.O., Luoma A., Modiste R.J., Nguyen Q.-D., Michel B.,
RA   Cejas P., Kadoch C., Jaffe J.D., Wucherpfennig K.W., Qi J., Liu X.-L.S.,
RA   Long H., Brown M.A., Carroll J.S., Brugge J.S., Bradner J.E., Michor F.,
RA   Polyak K.;
RT   "Synthetic lethal and resistance interactions with BET bromodomain
RT   inhibitors in triple-negative breast cancer.";
RL   Mol. Cell 78:1096-1113.e8(2020).
//